<?xml version="1.0" encoding="UTF-8"?>
<ref id="cit0058">
 <label>58.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Kawai</surname>
    <given-names>K</given-names>
   </name>, 
   <name name-style="western">
    <surname>Miyazaki</surname>
    <given-names>J</given-names>
   </name>, 
   <name name-style="western">
    <surname>Joraku</surname>
    <given-names>A</given-names>
   </name>, 
   <name name-style="western">
    <surname>Nishiyama</surname>
    <given-names>H</given-names>
   </name>, 
   <name name-style="western">
    <surname>Akaza</surname>
    <given-names>H</given-names>
   </name>
  </person-group>
  <article-title>Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine</article-title>. 
  <source>Cancer Sci</source>. 
  <year>2013</year>;
  <volume>104</volume>(
  <issue>1</issue>):
  <fpage>22</fpage>â€“
  <lpage>27</lpage>. doi:
  <pub-id pub-id-type="doi">10.1111/cas.12075</pub-id>.
  <pub-id pub-id-type="pmid">23181987</pub-id>
 </mixed-citation>
</ref>
